Literature DB >> 12407490

Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes.

Africa Holguín1, Vincent Soriano.   

Abstract

Naturally occurring polymorphisms at positions involved in resistance to antiretroviral agents are frequently seen in HIV-1 non-B subtypes. Although they do not seem to affect significantly the susceptibility to antiretroviral drugs in vitro, they may facilitate the selection of different pathways and/or a more rapid emergence of drug resistance and treatment failure under not fully suppressive treatment regimens.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12407490     DOI： 10.1310/7bwp-0x7f-nxna-qrnp

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN： 1528-4336


  5 in total

1.  Active-site mutations in the South african human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study.

Authors:  Salerwe Mosebi; Lynn Morris; Heini W Dirr; Yasien Sayed
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

2.  Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.

Authors:  Hiroyuki Gatanaga; Hirotaka Ode; Atsuko Hachiya; Tsunefusa Hayashida; Hironori Sato; Shinichi Oka
Journal:  Antimicrob Agents Chemother       Date:  2010-02-01       Impact factor: 5.191

3.  Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1.

Authors:  Dan Turner; Bluma Brenner; Daniela Moisi; Mervi Detorio; Raymond Cesaire; Takashi Kurimura; Haruyo Mori; Max Essex; Shlomo Maayan; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

4.  Genetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins.

Authors:  Paloma Troyano-Hernáez; Roberto Reinosa; Africa Holguín
Journal:  Front Microbiol       Date:  2022-07-14       Impact factor: 6.064

Review 5.  Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review.

Authors:  Madhavi Bhargava; Jorge Martinez Cajas; Mark A Wainberg; Marina B Klein; Nitika Pant Pai
Journal:  J Int AIDS Soc       Date:  2014-07-04       Impact factor: 5.396
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.